Turn Therapeutics Appoints Veteran Corporate Advisor Arthur Golden To Board Of Directors To Strengthen Governance and Strategic Growth

Turn Therapeutics, a clinical-stage biotechnology company focused on developing next-generation therapies for dermatology, wound care, and infectious diseases, has announced the appointment of Arthur Golden to its Board of Directors. Arthur Golden is a highly accomplished corporate advisor with extensive experience in mergers and acquisitions, shareholder relations, compliance, and corporate governance. He has served as a corporate director for several decades, most recently spending 24 years on the Board of Emerson Electric. During his tenure there, he chaired the Corporate Governance and Finance Committees and was also a member of the Executive Committee.

Golden currently serves as Senior Counsel at Davis Polk & Wardwell LLP, one of the world’s leading law firms. He was a partner at the firm for more than 40 years, where he advised Fortune 500 companies and emerging enterprises on transformative transactions, governance matters, litigation, and risk management. His professional expertise spans a wide range of sectors including life sciences, healthcare, consumer, industrial, and technology industries. Throughout his career, he has specialized in guiding multinational organizations through complex M&A transactions, cross-border governance issues, and shareholder engagement strategies.

Commenting on the appointment, Bradley Burnam, Chief Executive Officer of Turn Therapeutics, said that Arthur Golden brings an invaluable combination of legal, governance, and strategic experience to the company’s Board. He added that Golden’s long-standing experience working with global organizations in navigating growth, compliance, and capital market challenges will be instrumental as Turn advances its late-stage programs and expands its commercial footprint. Burnam emphasized that Golden’s guidance will help the company strengthen its governance framework and maintain focus on long-term growth and value creation.

Arthur Golden expressed his enthusiasm about joining the Board, noting that Turn Therapeutics is at an important stage of its development. He stated that sound governance, capital discipline, and regulatory focus will be key to sustaining the company’s growth in the years ahead. Golden praised Turn’s commitment to advancing clinically meaningful innovations within a responsible and well-structured framework and said he looks forward to contributing to the company’s mission and strategic progress as part of the Board.